{{Rsnum
|rsid=4148943
|Gene=CHST3
|Chromosome=10
|position=73769507
|Orientation=plus
|GMAF=0.3586
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 19.0 | 50.8 | 30.2
| HCB | 77.8 | 22.2 | 0.0
| JPT | 75.0 | 22.7 | 2.3
| YRI | 40.3 | 45.2 | 14.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 77.8 | 22.2 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4148943
|Name_s=CHST3:rs4148943 C>T; NM_004273.3:c.*1278C>T
|Gene_s=CHST3
|Feature=3' UTR
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: C Phenotype: The CHST3:rs4148943 C variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0001 Type of association: PD; CO
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111528
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4148943
|overall_frequency_n=47
|overall_frequency_d=128
|overall_frequency=0.367188
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}